| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 611 Gävleborg |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 26 | 2.3% | 88 | 7.6% | 32 | 2.8% | . | . | . | . | . | . | 1006 | 87.3% | 1152 | 100.0% |
| ASCUS | 44 | 9.4% | 183 | 39.3% | 123 | 26.4% | 3 | 0.6% | 3 | 0.6% | 2 | 0.4% | 108 | 23.2% | 466 | 100.0% |
| LSIL | 16 | 7.9% | 67 | 33.0% | 71 | 35.0% | . | . | . | . | 2 | 1.0% | 47 | 23.2% | 203 | 100.0% |
| Unclear atypia | . | . | . | . | 4 | 66.7% | 2 | 33.3% | . | . | . | . | . | . | 6 | 100.0% |
| ASC-H | . | . | 3 | 17.6% | 10 | 58.8% | 2 | 11.8% | 2 | 11.8% | . | . | . | . | 17 | 100.0% |
| HSIL | . | . | 7 | 29.2% | 17 | 70.8% | . | . | . | . | . | . | . | . | 24 | 100.0% |
| Totalt | 86 | 4.6% | 348 | 18.6% | 257 | 13.8% | 7 | 0.4% | 5 | 0.3% | 4 | 0.2% | 1161 | 62.2% | 1868 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M80703, M81403 |